Charles George Drake

This inventor holds 10 USPTO granted patents and 17 published patent applications, plus 1 CIPO patent and 2 EPO patents. Top assignees: Johns Hopkins University, St. Jude Children's Research Hospital, Aduro Biotech Inc.. Active years: 2013-2021.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Charles George Drake. Retrieved from https://idiyas.com/inventor/charles-george-drake

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 10 (Patent Applications = 17)

% Patents Active = 60.0

CIPO Patents = 1 (Patent Applications = 3)

EPO Patents = 2 (Patent Applications = 6)

Average Co-Inventor Count = 5.2

ph-index = 5

Forward Citations = 158(Granted Patents)

Company Filing History:

10 out of 3,801

Johns Hopkins University

patents

4 out of 281

St. Jude Children's Research Hospital

where one patent can have more than one assignee

Years Active: 2013-2021

Loading Chart...

10 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10934354 - Methods of increasing T cell immune response in the treatment of cancer (2021-03-02),

2. 10787513 - Methods for treatment comprising an antibody that binds CD223 protein (2020-09-29),

3. 10329617 - Compositions and methods for modulating an immune response (2019-06-25),

4. 9808516 - Immunogenic fusion proteins for the treatment of cancer (2017-11-07),

5. 9585957 - Adenosine receptor agonists and antagonists to modulate T cell responses (2017-03-07),

6. 9523126 - Compositions and methods for modulating an immune response (2016-12-20),

7. 9248170 - Immunogenic compositions and methods for treating neoplasia (2016-02-02),

8. 9132281 - Focused radiation for augmenting immune-based therapies against neoplasms (2015-09-15),

9. 9005629 - Method for treating cancer with an antibody to CD223 protein (2015-04-14),

10. 8551481 - Anti-cancer vaccine composition comprising an anti-CD223 antibody and kit comprising an anti-cancer vaccine and an anti-CD223 antibody (2013-10-08),

Title: The Groundbreaking Contributions of Inventor Charles George Drake

Introduction

Charles George Drake is a notable inventor based in Baltimore, MD, recognized for his significant contributions to the field of immunotherapy and cancer treatment. With a remarkable portfolio of 10 patents, Drake has played a crucial role in advancing medical science, particularly in enhancing T cell immune responses in cancer patients.

Latest Patents

Drake's latest patents include innovative methods aimed at increasing T cell immune response in cancer treatments. One of his notable inventions focuses on the combinations of anti-cancer antibodies and inhibitory antibodies to CD223, which have shown promise in overcoming immune suppression in cancer patients. His research involves the generation of these inhibitory antibodies in animals through the injection of CD223 fragments. Additionally, his work on methods for treatment comprising antibodies that bind to the CD223 protein emphasizes the benefits of anti-CD223 antibodies, which can also be produced in animals using similar techniques.

Career Highlights

Throughout his career, Charles George Drake has been affiliated with esteemed institutions such as The Johns Hopkins University and St. Jude Children's Research Hospital. His dedication to cancer research and immunotherapy has established him as a leading figure in his field.

Collaborations

Drake has collaborated with prominent professionals in the sector, including Drew M. Pardoll and Jonathan David Powell. These partnerships have been instrumental in fostering innovation and advancing research efforts in cancer immunotherapy.

Conclusion

Charles George Drake's innovative spirit and commitment to his work have resulted in significant advancements in cancer treatment techniques. His contributions reflect the vital role of inventors in the ongoing battle against cancer, paving the way for better therapeutic options for patients worldwide.

Profile summary based on public USPTO records.